吲哚并[3,2-B]咔唑-6-甲醛 | 172922-91-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 吲哚并[3,2-B]咔唑-6-甲醛
• 中文别名: 6-甲酰基吲哚并[3,2-B]咔唑；6-甲酰基吲哚并[3,2-b]咔唑
• 英文名称: 6-Formylindolo-(3,2-b)-carbazole
• 英文别名: FICZ；5,11-dihydroindolo[3,2-b]carbazole-6-carboxaldehyde；5,11-dihydroindolo[3,2-b]carbazole-12-carbaldehyde；5,11-Dihydroindolo[3,2-b]carbazole-6-carbaldehyde
• CAS: 172922-91-7
• 化学式: C₁₉H₁₂N₂O
• 分子量: 284.317
• InChiKey: ZUDXFBWDXVNRKF-UHFFFAOYSA-N

物化性质

• 沸点：
  630.3±35.0 °C(Predicted)
• 密度：
  1.463±0.06 g/cm3(Predicted)
• 溶解度：
  溶于DMSO（高达10mg/ml）。

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.6
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

制备方法与用途

生物活性

FICZ (6-Formylindolo[3,2-b]carbazole) 是一种有效的aryl hydrocarbon receptor (AhR) 激动剂，并可被AHR调节的细胞色素P4501酶有效地代谢。

靶点

Target	Value
AhR	()

体外研究

FICZ（0.01 nM-1 µM）单独或与50 nM MNF联合使用可诱导持续的CYP1A1活性，并通过线粒体依赖途径导致氧化应激和凋亡激活。在HepG2细胞中，低浓度的FICZ刺激细胞生长，而高浓度则抑制细胞生长。在CEH细胞系中，FICZ（10,000-30,000 nM）显著降低了CEH活力，并估计其LC50值为14,000 nM（95%置信区间）。FICZ在CEH培养物中的浓度依赖性影响EROD活性，其EC50值分别为3小时、8小时和24小时的0.016 nM、0.80 nM和11 nM。FICZ处理增加了亲本iPSC系和CYP1A1靶向克隆中CYP1A1转录表达的剂量依赖性增加。当FICZ抑制CYP1酶时，会导致AhR激活增强，表明当其代谢被阻断时，FICZ在细胞内积累。核输出和降解是AhR介导信号传导途径中的两个额外步骤。暴露于AhR激动剂会通过泛素/蛋白体降解途径下调表达AhR的细胞受体。

反应信息

• 作为反应物：
  描述：

  4,5-二甲氧基-2-硝基溴苄 、 吲哚并[3,2-B]咔唑-6-甲醛 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 以50%的产率得到
  参考文献：
  名称：

  Engineered Th17 Cell Differentiation Using a Photoactivatable Immune Modulator

  摘要：

  T helper 17 (Th17) cells, an important subset of CD4(+) T cells, help to eliminate extracellular infectious pathogens that have invaded our tissues. Despite the critical roles of Th17 cells in immunity, how the immune system regulates the production and maintenance of this cell type remains poorly understood. In particular, the plasticity of these cells or their dynamic ability to trans-differentiate into other CD4(+) T cell subsets remains mostly uncharacterized. Here, we report a synthetic immunology approach using a photoactivatable immune modulator (PIM) to increase Th17 cell differentiation on demand with spatial and temporal precision to help elucidate this important and dynamic process. In this chemical strategy, we developed a latent agonist that upon photochemical activation releases a small-molecule ligand that targets the aryl hydrocarbon receptor (AhR) and ultimately induces Th17 cell differentiation. We used this chemical tool to control AhR activation with spatiotemporal precision within cells and to modulate Th17 cell differentiation on demand using UV light illumination. We envision that this approach will enable an understanding of the dynamic functions and behaviors of Th17 cells in vivo during immune responses and in mouse models of inflammatory disease.

  DOI：

  10.1021/jacs.0c07485
• 作为产物：
  描述：

  ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate 在 lithium aluminium tetrahydride 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 52.5h， 生成 吲哚并[3,2-B]咔唑-6-甲醛
  参考文献：
  名称：

  Ah受体配体6-甲酰吲哚[3,2-b]咔唑代谢物的合成

  摘要：

  描述了芳烃受体高亲和力配体 6-甲酰基吲哚并 [3,2-b] 咔唑的五种单羟基化和二羟基化代谢物的合成。代谢物的结构是...

  DOI：

  10.1002/ejoc.200400087

文献信息

• [EN] 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE ET COMPOSÉS CORRESPONDANTS UTILISÉS EN TANQUE QUE AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) UTILISÉS POUR LE TRAITEMENT DE, P.EX., DE L'ANGIOGENÈSE IMPLIQUÉE OU DE TROUBLES INFLAMMATOIRES
  申请人：IKENA ONCOLOGY INC

  公开号：WO2021127302A1

  公开（公告）日：2021-06-24

  2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

  2-(1H-吲哚-3-甲酰基)-噻唑-4-羧酰胺衍生物及相应的咪唑、噁唑和噻吩衍生物以及相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。本说明书揭示了示例化合物的合成和表征以及其药理数据（例如第27至32页和59至219页；示例1至8；化合物1-1至1-97；表1-a、2和3）。
• [EN] 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 4-PHÉNYL-N-(PHÉNYL)THIAZOL-2-AMINE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) POUR LE TRAITEMENT, PAR EX., DE TROUBLE LIÉS À L'ANGIOGENÈSE OU INFLAMMATOIRES
  申请人：IKENA ONCOLOGY INC

  公开号：WO2021127301A1

  公开（公告）日：2021-06-24

  4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders.

  4-苯基-N-(苯基)噻唑-2-胺和4-(吡啶-3-基)-N-(苯基)噻唑-2-胺衍生物以及相应的噻二唑、噻吩、噁唑、噁二唑、咪唑和三唑衍生物和相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。
• SYNTHESIS OF DIINDOLYLMETHANES AND INDOLO[3,2-B]CARBAZOLES, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20160039754A1

  公开（公告）日：2016-02-11

  Described is a method to make diindolylmethanes and indolyl/pyrrolylmethanes, The method includes the steps of contacting an ether comprising an arylpropargyl moiety and an amine-protected, substituted or unsubstituted aniline moiety with a substituted or unsubstituted indol or a substituted or unsubstituted pyrrole, in the presence of a metal-containing catalyst, for a time and at a temperature to cause an annulation/arylation cascade reaction that yields a diindolylmethane or a indolyl/pyrrolylmethane. The resulting compounds are effective to modulate activity of arylhydrocarbon receptors, to inhibit activity of PCSK9, and to stimulate secretion of glucagon-like peptide 1 in mammals.

  描述了一种制备二吲哚基甲烷和吲哚基/吡咯基甲烷的方法。该方法包括以下步骤：在金属催化剂的存在下，使包含芳基炔丙基部分和胺保护的、取代的或未取代的苯胺部分的醚与取代的或未取代的吲哚或取代的或未取代的吡咯接触，接触一段时间和温度，以引发环化/芳基化级联反应，从而产生二吲哚基甲烷或吲哚基/吡咯基甲烷。所得化合物能有效调节芳基烃受体的活性，抑制PCSK9的活性，并刺激哺乳动物胰高血糖素样肽1的分泌。
• NOVEL ARYL HYDROCARBON RECEPTOR LIGANDS DERIVED FROM KYNURENINE
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20190135812A1

  公开（公告）日：2019-05-09

  The present invention relates to novel compounds which are aryl hydrocarbon receptor (AHR) ligands and uses thereof.

  这项发明涉及新型化合物，这些化合物是芳香烃受体（AHR）配体，并且其用途。
• ARYL HYDROCARBON RECEPTOR MODULATOR
  申请人：Ariagen, Inc.

  公开号：US20190307731A1

  公开（公告）日：2019-10-10

  Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R′ is H, CN, CH 2 (OH)R 0 , C m H 2m+1 , C n H 2n-1 , C n H 2n-3 , two R a are independently H or two R a together form ═O or ═N—W 3 —R 1 ; A is a C 6 to C 10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C 2 -C 10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, O, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C═N and interrupted by 1 to 3 heteroatoms selected from N, O, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C 6 to C 10 aromatic ring or a C 2 to C 10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, O, and S; and R is R c which is C-attached or R N which is N-attached. The compounds of formula (I) of the present invention can regulate AhR activity, and can be used to inhibit the growth of cancer cells and inhibit the metastasis and invasion of tumor cells.

  本发明揭示了一种化学式（I）的芳香烃受体调节剂及其药用可接受盐，其中R′为H、CN、CH2（OH）R0、CmH2m+1、CnH2n-1、CnH2n-3，两个Ra独立地为H或两个Ra共同形成═O或═N—W3—R1；A为未取代或取代1至3个R的C6至C10芳香环，或由N、O和S中选择的1至5个杂原子中断的C2-C10杂芳环，或含有C═N并由N、O和S中选择的1至3个杂原子中断的4至7个成员的非芳杂环，其中一个未取代或取代1至3个R；Q为R，或者是未取代或取代1至3个R并由N、O和S中断的C6至C10芳香环或C2至C10杂芳环；R为C-连接的Rc或N-连接的RN。本发明的化合物可以调节AhR活性，可用于抑制癌细胞的生长，以及抑制肿瘤细胞的转移和侵袭。